Cormedix Inc (HAM:19KA) Stock Price, Trades & News

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

Financial Strength

7/10

Name	Current	Vs Industry
Cash-To-Debt	1.23
Equity-to-Asset	0.54
Debt-to-Equity	0.33
Debt-to-EBITDA	0.66
Interest Coverage	69.87
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	2.36	Distress Grey Safe
Beneish M-Score	12.48	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	1147.3
	3-Year Book Growth Rate	58.4
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	-46.96

Momentum Rank

2/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	31.95
	9-Day RSI	38.55
	14-Day RSI	43.18
	3-1 Month Momentum %	18.1
	6-1 Month Momentum %	-35.48

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	2.98
	Quick Ratio	2.74
	Cash Ratio	1.38
	Days Inventory	137.17
	Days Sales Outstanding	106.23
	Days Payable	63.01

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-22.8
	Shareholder Yield %	-29.64

Profitability Rank

1/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	85.84
	Operating Margin %	48.41
	Net Margin %	45.25
	EBITDA Margin %	55.18
	FCF Margin %	48.66
	OCF Margin %	49.4
	ROE %	58.32
	ROA %	32.38
	ROIC %	57.04
	3-Year ROIIC %	35.51
	ROC (Joel Greenblatt) %	352.27
	ROCE %	42.71
	Years of Profitability over Past 10-Year	1
	Moat Score	2
	Tariff Resilience Score	6

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	3.62
	Forward PE Ratio	14.47
	PE Ratio without NRI	3.5
	Price-to-Owner-Earnings	3.69
	PS Ratio	1.72
	PB Ratio	1.38
	Price-to-Tangible-Book	15.68
	Price-to-Free-Cash-Flow	3.5
	Price-to-Operating-Cash-Flow	3.44
	EV-to-EBIT	3.24
	EV-to-EBITDA	2.87
	EV-to-Revenue	1.59
	EV-to-Forward-Revenue	1.74
	EV-to-FCF	2.99
	Price-to-GF-Value	0.12
	Price-to-Projected-FCF	1.65
	Price-to-Graham-Number	1.57
	Price-to-Net-Current-Asset-Value	131.72
	Earnings Yield (Greenblatt) %	30.9
	FCF Yield %	29.24

Financials (Next Earnings Date:2026-08-07 Est.)

Annual Quarterly TTM

HAM:19KA's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Cormedix Inc Executives

Details

GF Value™: €56.66

HAM:19KA

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 3 Severe warning signs with 19KA. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	343.355
	EPS (TTM) (€)	1.826
	Beta	-
	3-Year Sharpe Ratio	-
	3-Year Sortino Ratio	-
	Volatility %	-
	14-Day RSI	43.18
	14-Day ATR (€)	0.245592
	20-Day SMA (€)	7.189
	12-1 Month Momentum %	-
	52-Week Range (€)	5.2 - 10.8
	Shares Outstanding (Mil)	78.45

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	5
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Cormedix Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Cormedix Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings conference call for 2026	2026-11-12 08:30	In 134 days
Third quarter earnings results for 2026	2026-11-12	In 133 days
Second quarter earnings conference call for 2026	2026-08-07 08:30	In 37 days
Second quarter earnings results for 2026	2026-08-07	In 36 days
General meeting for 2026	2026-06-23 09:00	7.23 (+0.00%)
Jefferies Global Healthcare Conference	2026-06-03 16:20	7.24 (+0.00%)
RBC Capital Markets Global Healthcare Conference	2026-05-20 11:00	6.19 (+0.00%)
First quarter earnings conference call for 2026	2026-05-14 08:30	6.36 (+0.00%)
First quarter earnings results for 2026	2026-05-14	6.36 (+0.00%)
CORMEDIX TO PARTICPATE IN NEEDHAM VIRTUAL HEALTHCARE CONFERENCE	2026-04-14 15:00	5.90 (+0.00%)

Show

Entries

Cormedix Inc Frequently Asked Questions

What is Cormedix Inc(HAM:19KA)'s stock price today?

The current price of HAM:19KA is €6.59. The 52 week high of HAM:19KA is €10.80 and 52 week low is €5.20.

When is next earnings date of Cormedix Inc(HAM:19KA)?

The next earnings date of Cormedix Inc(HAM:19KA) is 2026-08-07 Est..

Does Cormedix Inc(HAM:19KA) pay dividends? If so, how much?

Cormedix Inc(HAM:19KA) does not pay dividend.

Press Release

	Subject	Date
	Halper Sadeh LLC Encourages CorMedix Inc. Shareholders to Contact the Firm to Discuss Their Rights	2025-10-22
	CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is Investigating CorMedix, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm	2022-03-18
	DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against CorMedix Inc. and Encourages Investors to Contact the Firm	2021-09-17
	CRMD Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds CorMedix Inc. Shareholders Class Action and Lead Plaintiff Deadline: September 20, 2021	2021-09-17
	CRMD FINAL DEADLINE MONDAY: ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages CorMedix Inc. Investors with Losses to Secure Counsel Before Important September 20 Deadline in Securities Class Action - CRMD	2021-09-16
	MONDAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against CorMedix Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm	2021-09-16
	SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against CorMedix Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm	2021-09-15
	EXPANDED CLASS PERIOD: Robbins Geller Rudman & Dowd LLP Announces that CorMedix Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – CRMD	2021-09-15
	Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against CorMedix Inc. (CRMD)	2021-09-15
	CRMD INVESTOR LAWSUIT FILING DEADLINE SEPTEMBER 20, 2021: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against CorMedix Inc.	2021-09-15

10/Page

Articles on Cormedix Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.